Iomeprol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 13:21, 22 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Iomeprol
Clinical data
Trade namesImeron
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 1-N,3-N-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-methylacetamido)-2,4,6-triiodobenzene-1,3-dicarboxamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H22I3N3O8
Molar mass777.089 g·mol−1
3D model (JSmol)
  • Ic1c(c(I)c(c(I)c1N(C(=O)CO)C)C(=O)NCC(O)CO)C(=O)NCC(O)CO

Iomeprol is an iodinated molecule used as a contrast medium.

It is sold under the trade name Imeron, with the published formulations: Pharmaplan iodine content 250 mg, 300 mg, 350 mg and 400 mg/ml.[1]

It is classified as a water-soluble, nephrotrophic, low osmolar X-ray contrast medium.[1] The low osmolar non-ionic agents are better tolerated and less likely to cause side-effects than the high osmolar ionic agents.[1]

References

  1. ^ a b c South African medicines formulary. Rossiter, Dawn., University of Cape Town. Division of Clinical Pharmacology., South African Medical Association (1998- ). Health and Medical Publishing Group. (11th ed.). Rondebosch, South Africa: Health and Medical Pub. Group of the South African Medical Association. 2014. ISBN 9781875098309. OCLC 869772940.{{cite book}}: CS1 maint: others (link)